News
06-02-2012, 12:02 AM
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.
More... (http://www.news-medical.net/news/20120602/Agendia-launches-ColoPrint-microarray-based-18-gene-expression-signature-for-colon-cancer.aspx)
More... (http://www.news-medical.net/news/20120602/Agendia-launches-ColoPrint-microarray-based-18-gene-expression-signature-for-colon-cancer.aspx)